BRAF and thyroid gland undifferentiated (anaplastic) carcinoma: Trametinib is approved for the treatment of unresectable/metastatic melanoma (with a BRAF V600 mutation), advanced non-small cell lung cancer (with a BRAF V600 mutation), and advanced anaplastic thyroid cancer (with a BRAF V600 mutation), all in combination with the BRAF-targeted kinase inhibitor dabrafenib.